ADXN Relative Valuation
ADXN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ADXN is overvalued; if below, it's undervalued.
Historical Valuation
Addex Therapeutics Ltd (ADXN) is now in the Fair zone, suggesting that its current forward PS ratio of 4.08 is considered Fairly compared with the five-year average of -1.42. The fair price of Addex Therapeutics Ltd (ADXN) is between 6.62 to 12.57 according to relative valuation methord.
Relative Value
Fair Zone
6.62-12.57
Current Price：8.38
Fair
0.00
PE
1Y
3Y
5Y
Trailing
Forward
-1.21
EV/EBITDA
Addex Therapeutics Ltd. (ADXN) has a current EV/EBITDA of -1.21. The 5-year average EV/EBITDA is -1.00. The thresholds are as follows: Strongly Undervalued below -2.61, Undervalued between -2.61 and -1.80, Fairly Valued between -0.20 and -1.80, Overvalued between -0.20 and 0.61, and Strongly Overvalued above 0.61. The current Forward EV/EBITDA of -1.21 falls within the Historic Trend Line -Fairly Valued range.
-1.19
EV/EBIT
Addex Therapeutics Ltd. (ADXN) has a current EV/EBIT of -1.19. The 5-year average EV/EBIT is -1.06. The thresholds are as follows: Strongly Undervalued below -2.73, Undervalued between -2.73 and -1.90, Fairly Valued between -0.22 and -1.90, Overvalued between -0.22 and 0.61, and Strongly Overvalued above 0.61. The current Forward EV/EBIT of -1.19 falls within the Historic Trend Line -Fairly Valued range.
4.08
PS
Addex Therapeutics Ltd. (ADXN) has a current PS of 4.08. The 5-year average PS is 17.30. The thresholds are as follows: Strongly Undervalued below -27.90, Undervalued between -27.90 and -5.30, Fairly Valued between 39.89 and -5.30, Overvalued between 39.89 and 62.49, and Strongly Overvalued above 62.49. The current Forward PS of 4.08 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Addex Therapeutics Ltd. (ADXN) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.18. The thresholds are as follows: Strongly Undervalued below -5.14, Undervalued between -5.14 and -3.66, Fairly Valued between -0.70 and -3.66, Overvalued between -0.70 and 0.77, and Strongly Overvalued above 0.77. The current Forward P/OCF of 0.00 falls within the Overvalued range.
0.00
P/FCF
Addex Therapeutics Ltd. (ADXN) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.82. The thresholds are as follows: Strongly Undervalued below -4.43, Undervalued between -4.43 and -3.13, Fairly Valued between -0.52 and -3.13, Overvalued between -0.52 and 0.78, and Strongly Overvalued above 0.78. The current Forward P/FCF of 0.00 falls within the Overvalued range.
Addex Therapeutics Ltd (ADXN) has a current Price-to-Book (P/B) ratio of 103.38. Compared to its 3-year average P/B ratio of 26.85 , the current P/B ratio is approximately 285.10% higher. Relative to its 5-year average P/B ratio of 16.96, the current P/B ratio is about 509.65% higher. Addex Therapeutics Ltd (ADXN) has a Forward Free Cash Flow (FCF) yield of approximately -23.57%. Compared to its 3-year average FCF yield of -101.72%, the current FCF yield is approximately -76.83% lower. Relative to its 5-year average FCF yield of -87.55% , the current FCF yield is about -73.08% lower.
103.38
P/B
Median3y
26.85
Median5y
16.96
-23.57
FCF Yield
Median3y
-101.72
Median5y
-87.55
Competitors Valuation Multiple
The average P/S ratio for ADXN's competitors is 0.82, providing a benchmark for relative valuation. Addex Therapeutics Ltd Corp (ADXN) exhibits a P/S ratio of 4.08, which is 400.00% above the industry average. Given its robust revenue growth of -65.48%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ADXN increased by 19.72% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.26K to -5.39K.
The secondary factor is the Revenue Growth, contributed -65.48%to the performance.
Overall, the performance of ADXN in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Addex Therapeutics Ltd (ADXN) currently overvalued or undervalued?
What is Addex Therapeutics Ltd (ADXN) fair value?
How does ADXN's valuation metrics compare to the industry average?
What is the current P/B ratio for Addex Therapeutics Ltd (ADXN) as of Dec 05 2025?
What is the current FCF Yield for Addex Therapeutics Ltd (ADXN) as of Dec 05 2025?
What is the current Forward P/E ratio for Addex Therapeutics Ltd (ADXN) as of Dec 05 2025?